List view / Grid view
The Genome Aggregation Database (gnomAD) Consortium has released seven papers leveraging its database to study genetic variants and their potential for guiding discovery of safer drugs.
Collaboration between scientists, illustrators and simulators has culminated in highly detailed three-dimensional (3D) models of SARS-CoV-2.
Scientists have designed a high affinity antibody for pathogenic amyloid beta oligomers, a key driver of Alzheimer’s disease, for use in further research and as a potential diagnostic tool.
The stem cells in-depth focus includes articles on using computational approaches expand the applications of stem-cell therapies and how organoids could be used to speed up the drug discovery process with a focus on retinal disease.
In this issue authors discuss the development of COVID-19 antibody therapies, how high-throughput screening enhances research at the Crick Institute and why combinations of immuno-oncology drugs could revolutionise treatment of advanced cancers. Also included in the issue are articles on stem cells and imaging.
Scientists have developed a method for designing artificial proteins that tell the immune system which antibodies to produce so could enhance vaccine design.
Researchers are utilising computers to aid in their investigations into a COVID-19 treatment. Here, we highlight three studies using simulations, calculations and AI to identify a drug to combat the coronavirus.
The COVID-19 Protein Portal, established by UKRI and Wellcome, will allow scientists in the UK to access protein reagents needed for research.
A novel software made by scientists can be used for the analysis of specific lipid groups and lipid signal molecules which can enable their characterisation with mass spectrometry.
A new AI tool has been created by researchers to identify the best treatment courses and doses for bacterial or viral infections, such as COVID-19.
A group of researchers has created a free library of 14,000 known macrolactones for other scientists to use in drug development.
The enterprise revealed that it has made its COVID-19 Drug Repurposing Database open-access to aid in the search for an effective therapeutic.
Researchers at MIT have developed a mathematical model that can calculate whether diabetes treatments in pre-clinical trials will be successful in humans.
A collaboration aims to utilise a compound library of 15,000 clinically-ready molecules and screen then against three COVID-19 targets.
In light of the COVID-19 pandemic, the creators of the Clinical Research Navigator (CRN) tool have offered free access to their system for biomedical researchers.
